Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper

Currently two intravitreally applied corticosteroids (dexamethasone and fluocinolone) are licensed in Germany for treatment of diabetic macular oedema (DME). The use of DEX implant for DME in daily clinical practice has not been defined in detail. Following a Delphi panel survey, a group of retina e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Klinische Monatsblatter fur Augenheilkunde Jg. 238; H. 1; S. 73
Hauptverfasser:	Augustin, Albert J, Feltgen, Nicolas, Haritoglou, Christos, Hoerauf, Hans, Maier, Mathias M, Mardin, Christian Yahya, Schargus, Marc
Format:	Journal Article
Sprache:	Deutsch
Veröffentlicht:	Germany 01.01.2021
Schlagworte:	Angiogenesis Inhibitors - therapeutic use Clinical Decision-Making Consensus Dexamethasone - therapeutic use Diabetes Mellitus Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Drug Implants Germany Glucocorticoids - therapeutic use Humans Intravitreal Injections Macular Edema - drug therapy Macular Edema - etiology Vascular Endothelial Growth Factor A Germany
ISSN:	1439-3999, 1439-3999
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!